Swedish Orphan Biovitrum appoints president and ceo

Geoffrey McDonough takes the role, joining the firm from Genzyme

Geoffrey McDonough, currently Genzyme’s president of Europe, Middle East and Africa (EMEA), will move Swedish Orphan Biovitrum (Sobi) as president and ceo on 15 August. He will succeed Kennet Rooth, who has been acting ceo since the beginning of the year.

McDonough has held several leading positions within Genzyme in the US since 2002, beginning his career with the firm in corporate development.

‘Geoff is well-recognised for his solid and broad commercial and clinical expertise and for his background in the orphan drug and niche speciality market,’ said Bo Jesper Hansen, chairman of Sobi.

‘He will lead Sobi toward our vision of becoming the leading niche speciality pharmaceutical company in Europe.’

You may also like

Research & Development

Sobi Orfadin capsules approved in Saudi Arabia

Swedish Orphan Biovitrum's orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1
Manufacturing

Sobi signs manufacturing agreements with Pfizer

Sobi is dedicated to developing and delivering innovative therapies for rare diseases
Pharmaceutical

Cytiva and Fida Biosystems unite to improve molecular insight for faster drug discovery

The collaboration will combine complementary and orthogonal approaches to simplify workflows and improve confidence in experimental results
Manufacturing

SeaBeLife partners with Unither Pharmaceuticals for ophthalmic drug production

The new partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate SBL03 to treat degenerative disorders of the retina, such as dry age-related macular degeneration
Pharmaceutical

SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain

Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Pharmaceutical

Samsung Bioepis expands European biosimilar portfolio with OBODENCE and XBRYK launches

The products, targeting osteoporosis and bone-related complications in cancer, strengthen access to affordable care and expand the company’s direct sales footprint across endocrinology and oncology
Subscribe now